Nivolumab-Induced Diabetic Ketoacidosis: A Case Report
Author Information
Author(s): Jung Yungee, Lau Anthony, Bednarczyk Joseph
Primary Institution: Vancouver General Hospital
Hypothesis
Can nivolumab therapy lead to diabetic ketoacidosis in patients without prior diabetes?
Conclusion
Nivolumab can induce diabetic ketoacidosis even in patients with no prior history of diabetes, necessitating careful monitoring.
Supporting Evidence
- Nivolumab is an immune checkpoint inhibitor that can cause various immune-related adverse effects.
- Diabetic ketoacidosis was diagnosed based on laboratory findings and clinical symptoms.
- The patient required ongoing insulin therapy after the diagnosis of new-onset type 1 diabetes.
Takeaway
A patient developed a serious condition called diabetic ketoacidosis after taking a cancer treatment called nivolumab, even though he had never had diabetes before.
Methodology
Case report detailing the clinical presentation, diagnosis, and management of a patient with nivolumab-induced diabetic ketoacidosis.
Limitations
The case report is based on a single patient, limiting generalizability.
Participant Demographics
70-year-old Caucasian male with metastatic esophageal adenocarcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website